DOL Verified Employer

Lantern Pharma, Inc. - Chief Executives

Government-verified salary data from 15 US Department of Labor filings.

Median Salary
$202,966
1 DOL filings
TX Approval Rate 100.0% · most recent FY 2025
Median Salary
$202,966
Certified filings
DOL Filings
1
Certified: 15
Unique Job Titles
9
SOC occupations
Approval Rate
100.0%
Certified vs filed

Salary Range

Based on 1 certified filings
Insufficient data for salary range.

Salary Trend

FY2017 - FY2025

Salaries by Job Title

9 occupations with DOL-filed salary data
Job TitleFilingsMedian Salaryvs MarketSalary Range
19-1042.00 3 $79,000 N/A
Insufficient data for salary range.
General and Operations Managers 2 N/A N/A
Insufficient data for salary range.
15-1111 2 $68,750 N/A
$65,000$65,000$68,750$72,500$72,500
19-1029.01 2 $76,400 N/A
Insufficient data for salary range.
27-3031.00 2 $65,077 N/A
$52,000$52,000$65,077$78,153$78,153
Chief Executives 1 $202,966 -1.7%
Insufficient data for salary range.
15-1199.06 1 $69,000 N/A
Insufficient data for salary range.
Biological Scientists, All Other 1 $65,000 -30.4%
Insufficient data for salary range.
Medical Scientists, Except Epidemiologists 1 $70,000 -30.4%
Insufficient data for salary range.

Individual DOL Filings for Chief Executives at Lantern Pharma, Inc.

DateSalaryPrevailing WageLevelLocationEducationStatusSource
Jan 2018 $202,966 $199,534 - DALLAS TX N/A Certified LCA

DOL data does not contain worker names. Only employer, salary, and job details are shown.

Hiring Activity

Full tracker →
Job Search

Open Positions at Lantern Pharma, Inc.

Browse current openings and compare them against the government-filed salary data above.

Source: US Department of Labor, Office of Foreign Labor Certification (OFLC) public disclosure files (PERM Form ETA-9089 and LCA Form ETA-9035), and US Bureau of Labor Statistics Occupational Employment and Wage Statistics (OEWS). Salary figures represent employer filings and government survey estimates, not individual worker pay.

Data covers DOL filings from 2014 to 2025.